Healthcare act affirmed; Synapse adds jobs in Ohio; Efficiencies drive GSK inhaler plant;

> In a surprise decision, the Supreme Court has upheld the affordable healthcare act. Story

> Devicemaker Synapse Biomedical is using a $5.1 million state tax break to add 60 jobs to its Oberlin, OH, plant. Story

> Six workers can now handle four assembly lines that turn out 220,000 inhalers a day because of efficiencies built into GlaxoSmithKline's ($GSK) respiratory-drug plant in Ware, England. Story

> Suzhou Pharma will open a quality assurance operation in Lyndhurst, NJ, in an effort to marry Western cGMP know-how with Asian production expertise. Story

And Finally... The FDA user fee law bans 28 chemicals sold at corner stores as hygiene products, incense or plant food that are often used in synthetic drugs known as "bath salts." Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.